Breast Cancer Metabolism and Mitochondrial Activity: The Possibility of Chemoprevention with Metformin

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Cazzaniga, Massimiliano ^a   Bonanni, Bernardo ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

BREAST CANCER; CANCER CELL; CANCER PREVENTION; CELL ACTIVITY; CELL METABOLISM; CELL PROLIFERATION; CHEMOPROPHYLAXIS; DRUG MECHANISM; ENERGY; HUMAN; MITOCHONDRION; REVIEW; TUMOR GROWTH; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; METABOLISM;

BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; HUMANS; METFORMIN; MITOCHONDRIA;

EID: 84947461275     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/972193     Document Type: Review

References (85)

1. S. Byler, S. Goldgar, S. Heerboth et al., "Genetic and epigenetic aspects of breast cancer progression and therapy," Anticancer Research, vol. 34, no. 3, pp. 1071-1077, 2014.
2. S. Romero-Garcia, J. S. Lopez-Gonzalez, J. L. Bez-Viveros, D. Aguilar-Cazares, and H. Prado-Garcia, "Tumor cell metabolism: an integral view," Cancer Biology and Therapy, vol. 12, no. 11, pp. 939-948, 2011.
3. W. H. Koppenol, P. L. Bounds, and C. V. Dang, "Otto Warburg's contributions to current concepts of cancer metabolism," Nature Reviews Cancer, vol. 11, no. 5, pp. 325-337, 2011.
4. M. G. V. Heiden, L. C. Cantley, and C. B. Thompson, "Understanding the warburg effect: the metabolic requirements of cell proliferation," Science, vol. 324, no. 5930, pp. 1029-1033, 2009.
5. T. Pfeiffer, S. Schuster, and S. Bonhoeffer, "Cooperation and competition in the evolution of ATP-producing pathways," Science, vol. 292, no. 5516, pp. 504-507, 2001.
6. O.Warburg, "On the origin of cancer cells," Science, vol. 123, no. 3191, pp. 309-314, 1956.
7. R. Moreno-Snchez, S. Rodruez-Enruez, A. Mar-Hernndez, and E. Saavedra, "Energy metabolism in tumor cells," FEBS Journal, vol. 274, no. 6, pp. 1393-1418, 2007.
8. I. A. Barbosa, N. G.Machado, A. J. Skildum,P.M. Scott, andP. J. Oliveira, "Mitochondrial remodeling in cancer metabolism and survival: potential for new therapies," Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, vol. 1826, no. 1, pp. 238-254, 2012.
9. A.D. Ortega,M. Snchez-Arag,D.Giner-Snchez, L. Snchez-Cenizo, I. Willers, and J. M. Cuezva, "Glucose avidity of carcinomas," Cancer Letters, vol. 276, no. 2, pp. 125-135, 2009.
10. N. D. Amoêdo, J. P.Valencia, M. F. Rodrigues, A. Galina, and F. D. Rumjanek, "How does the metabolism of tumour cells differ from that of normal cells," Bioscience Reports, vol. 33, no. 6, pp. 865-873, 2013.
11. J. Zheng, "Energy metabolism of cancer: glycolysis versus oxidative phosphorylation (review)," Oncology Letters, vol. 4, no. 6, pp. 1151-1157, 2012.
12. S. Patergnani, F. Baldassari, E. De Marchi, A. Karkucinska-Wieckowska, M. R. Wieckowski, and P. Pinton, "Methods to monitor and compare mitochondrial and glycolytic ATP production," Methods in Enzymology, vol. 542, pp. 313-332, 2014.
13. G. Bonuccelli, A. Tsirigos,D.Whitaker-Menezes et al., "Ketones and lactate 'fuel' tumor growth and metastasis: evidence that epithelial cancer cells use oxidativemitochondrial metabolism," Cell Cycle, vol. 9, no. 17, pp. 3506-3514, 2010.
14. S. Rodruez-Enruez, L. Carreño-Fuentes, J. C. Gallardo-Prez et al., "Oxidative phosphorylation is impaired by prolonged hypoxia in breast and possibly in cervix carcinoma," International Journal of Biochemistry & Cell Biology, vol. 42, no. 10, pp. 1744-1751, 2010.
15. L. M. R. Ferreira, "Cancer metabolism: the Warburg effect today," Experimental andMolecular Pathology, vol. 89, no. 3, pp. 372-380, 2010.
16. M. Lpez-Lzaro, "The warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen" Anti-Cancer Agents in Medicinal Chemistry, vol. 8, no. 3, pp. 305-312, 2008.
17. R. J. DeBerardinis, J. J. Lum, G. Hatzivassiliou, and C. B. Thompson, "The biology of cancer: metabolic reprogramming fuels cell growth and proliferation," Cell Metabolism, vol. 7, no. 1, pp. 11-20, 2008.
18. P. S. Ward and C. B.Thompson, "Metabolic reprogramming: a cancer hallmark evenWarburg did not anticipate," Cancer Cell, vol. 21, no. 3, pp. 297-308, 2012.
19. E. Laconi, "Theevolving concept of tumor microenvironments," BioEssays, vol. 29, no. 8, pp. 738-744, 2007.
20. A. L. Harris, "Hypoxia-a key regulatory factor in tumour growth," Nature Reviews Cancer, vol. 2, no. 1, pp. 38-47, 2002.
21. G. L. Semenza, "Targeting HIF-1 for cancer therapy," Nature Reviews Cancer, vol. 3, no. 10, pp. 721-732, 2003.
22. S. Y. C. Choi, C. C. Collins, P. W. Gout, and Y. Wang, "Cancergenerated lactic acid: a regulatory, immunosuppressive metabolite" The Journal of Pathology, vol. 230, no. 4, pp. 350-355, 2013.
23. A. Mayer and P. Vaupel, "Hypoxia, lactate accumulation, and acidosis: siblings or accomplices driving tumor progression and resistance to therapy" Advances in Experimental Medicine and Biology, vol. 789, pp. 203-209, 2013.
24. R. A. Gatenby, K. Smallbone, P. K. Maini et al., "Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer," British Journal of Cancer, vol. 97, no. 5, pp. 646-653, 2007.
25. K. Mekhail, L. Rivero-Lopez, M. Khacho, and S. Lee, "Restriction of rRNA synthesis by VHL maintains energy equilibrium under hypoxia," Cell Cycle, vol. 5, no. 20, pp. 2401-2413, 2006.
26. M. Laplante and D. M. Sabatini, "MTOR signaling in growth control and disease," Cell, vol. 149, no. 2, pp. 274-293, 2012.
27. D.Daye andK. E.Wellen, "Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis," Seminars in Cell & Developmental Biology, vol. 23, no. 4, pp. 362-369, 2012.
28. D. R. Wise, R. J. Deberardinis, A. Mancuso et al., "Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 48, pp. 18782-18787, 2008.
29. J.-B. Wang, J.W. Erickson, R. Fuji et al., "Targeting mitochondrial glutaminase activity inhibits oncogenic transformation," Cancer Cell, vol. 18, no. 3, pp. 207-219, 2010.
30. P. Gao, I. Tchernyshyov, T.-C. Chang et al., "c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutaminemetabolism," Nature, vol. 458, no. 7239, pp. 762-765, 2009.
31. M. R. Reynolds, A. N. Lane, B. Robertson et al., "Control of glutamine metabolism by the tumor suppressor Rb," Oncogene, vol. 33, no. 5, pp. 556-566, 2014.
32. P. L. Pedersen, "Tumor mitochondria and the bioenergetics of cancer cells," Progress in Experimental Tumor Research, vol. 22, pp. 190-274, 1978.
33. M. Skrti, S. Sriskanthadevan, B. Jhas et al., "Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia," Cancer Cell, vol. 20, no. 5, pp. 674-688, 2011.
34. D. R. Wise and C. B. Thompson, "Glutamine addiction: a new therapeutic target in cancer," Trends in Biochemical Sciences, vol. 35, no. 8, pp. 427-433, 2010.
35. F.Weinberg andN. S. Chandel, "Mitochondrialmetabolismand cancer," Annals of the New York Academy of Sciences, vol. 1177, pp. 66-73, 2009.
36. R. W. Taylor and D. M. Turnbull, "Mitochondrial DNA mutations in human disease," Nature Reviews Genetics, vol. 6, no. 5, pp. 389-402, 2005.
37. R. Scatena, "Mitochondria and cancer: a growing role in apoptosis, cancer cell metabolism and dedifferentiation," Advances in ExperimentalMedicine and Biology, vol. 942, pp. 287-308, 2012.
38. P. J. Pollard, J. J. Brière,N. A. Alamet al., "Accumulation ofKrebs cycle intermediates and over-expression of HIF1 in tumours which result from germline FH and SDH mutations," Human Molecular Genetics, vol. 14, no. 15, pp. 2231-2239, 2005.
39. K. Bensaad and K. H. Vousden, "p53: new roles in metabolism," Trends in Cell Biology, vol. 17, no. 6, pp. 286-291, 2007.
40. S. J. Yeung, J. Pan, and M.-H. Lee, "Roles of p53, MYC and HIF-1 in regulating glycolysis-the seventh hallmark of cancer," Cellular and Molecular Life Sciences, vol. 65, no. 24, pp. 3981-3999, 2008.
41. R. Scatena, P. Bottoni, A. Pontoglio, L. Mastrototaro, and B. Giardina, "Glycolytic enzyme inhibitors in cancer treatment," Expert Opinion on Investigational Drugs, vol. 17,no. 10, pp. 1533-1545, 2008.
42. S. Fulda, L. Galluzzi, and G. Kroemer, "Targeting mitochondria for cancer therapy," Nature Reviews Drug Discovery, vol. 9, no. 6, pp. 447-464, 2010.
43. E. Zhang, C. Zhang, Y. Su, T. Cheng, and C. Shi, "Newly developed strategies formultifunctionalmitochondria-targeted agents in cancer therapy," Drug Discovery Today, vol. 16, no. 3-4, pp. 140-146, 2011.
44. D.Whitaker-Menezes, U. E.Martinez-Outschoorn,N. Flomenberg et al., "Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects ofmetformin in tumor tissue," Cell Cycle, vol. 10, no. 23, pp. 4047-4064, 2011.
45. S.Becker, L. Dossus, andR. Kaaks, "Obesity relatedhyperinsulinaemia and hyperglycaemia and cancer development," Archives of Physiology and Biochemistry, vol. 115, no. 2, pp. 86-96, 2009.
46. K. Esposito, P. Chiodini, A. Colao, A. Lenzi, and D. Giugliano, "Metabolic syndrome and risk of cancer: a systematic review and meta-analysis," Diabetes Care, vol. 35, no. 11, pp. 2402-2411, 2012.
47. K. Esposito, P. Chiodini, A. Capuano et al., "Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis," Menopause, vol. 20, no. 12, pp. 1301-1309, 2013.
48. H. Cheong, C. Lu, T. Lindsten, and C. B.Thompson, "Therapeutic targets in cancer cell metabolism and autophagy," Nature Biotechnology, vol. 30, no. 7, pp. 671-678, 2012.
49. M. G. Vander Heiden, "Targeting cancer metabolism: a therapeutic window opens," Nature Reviews Drug Discovery, vol. 10, no. 9, pp. 671-684, 2011.
50. A. DeCensi, M. Puntoni, P. Goodwin et al., "Metformin and cancer risk in diabetic patients: a systematic review and metaanalysis," Cancer Prevention Research, vol. 3, no. 11, pp. 1451-1461, 2010.
51. M. Cazzaniga, B. Bonanni, A. Guerrieri-Gonzaga, and A. Decensi, "Is it time to test metformin in breast cancer clinical trials" Cancer Epidemiology Biomarkers & Prevention, vol. 18, no. 3, pp. 701-705, 2009.
52. B. Bonanni, M. Puntoni, M. Cazzaniga et al., "Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial," Journal of Clinical Oncology, vol. 30, no. 21, pp. 2593-2600, 2012.
53. A. F. G. Cicero, E. Tartagni, and S. Ertek, "Metformin and its clinical use: new insights for an old drug in clinical practice," Archives of Medical Science, vol. 8, no. 5, pp. 907-917, 2012.
54. S. Suissa and L. Azoulay, "Metformin and cancer: mounting evidence against an association," Diabetes Care, vol. 37, no. 7, pp. 1786-1788, 2014.
55. C. Bosetti, M. Franchi, F. Nicotra et al., "Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databases," Pharmacoepidemiology and Drug Safety, vol. 24, no. 7, pp. 771-778, 2015.
56. I. Pernicova and M. Korbonits, "Metformin-mode of action and clinical implications for diabetes and cancer," Nature Reviews Endocrinology, vol. 10, no. 3, pp. 143-156, 2014.
57. R. J. O. Dowling, S. Niraula, M. C. Chang et al., "Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study," Breast Cancer Research, vol. 17, article 32, 2015.
58. G. Zhou, R. Myers, Y. Li et al., "Role of AMP-activated protein kinase in mechanism of metformin action," The Journal of Clinical Investigation, vol. 108, no. 8, pp. 1167-1174, 2001.
59. F. M. Giardiello, J. D. Brensinger, A. C. Tersmette et al., "Very high risk of cancer in familial Peutz-Jeghers syndrome," Gastroenterology, vol. 119, no. 6, pp. 1447-1453, 2000.
60. S. M. Hadad, P. Coates, L. B. Jordan et al., "Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial," Breast Cancer Research and Treatment, vol. 150, no. 1, pp. 149-155, 2015.
61. D. G.Hardie andD. R.Alessi, "LKB1 andAMPKand the cancermetabolism link-ten years after," BMC Biology, vol. 11, article 36, 2013.
62. B. Faubert, G. Boily, S. Izreig et al., "AMPK is a negative regulator of the warburg effect and suppresses tumor growth in vivo," Cell Metabolism, vol. 17, no. 1, pp. 113-124, 2013.
63. J. G. Boyle, I. P. Salt, and G. A. McKay, "Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target," Diabetic Medicine, vol. 27, no. 10, pp. 1097-1106, 2010.
64. J. Liang, S. H. Shao, Z.-X. Xu et al., "The energy sensing LKB1-AMPK pathway regulates p27kip1 phosphorylation mediating the decision to enter autophagy or apoptosis," Nature Cell Biology, vol. 9, no. 2, pp. 218-224, 2007.
65. C.Algire, L. Amrein,M.Bazile, S. David, M. Zakikhani, andM. Pollak, "Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo," Oncogene, vol. 30, no. 10, pp. 1174-1182, 2011.
66. L. Galluzzi, O. Kepp, and G. Kroemer, "TP53 and MTOR crosstalk to regulate cellular senescence," Aging, vol. 2, no. 9, pp. 535-537, 2010.
67. M.C.Maiuri, L. Galluzzi, E. Morselli,O.Kepp, S. A. Malik, and G. Kroemer, "Autophagy regulation by p53," Current Opinion in Cell Biology, vol. 22, no. 2, pp. 181-185, 2010.
68. S. Pavlides, D.Whitaker-Menezes, R. Castello-Cros et al., "The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma," Cell Cycle, vol. 8, no. 23, pp. 3984-4001, 2009.
69. U. E. Martinez-Outschoorn, R. G. Pestell, A. Howell et al., "Energy transfer in 'parasitic' cancer metabolism:mitochondria are the powerhouse and Achilles' heel of tumor cells," Cell Cycle, vol. 10, no. 24, pp. 4208-4216, 2011.
70. U. E. Martinez-Outschoorn, M. Prisco, A. Ertel et al., "Ketones and lactate increase cancer cell 'stemness', driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via metabolo-genomics," Cell Cycle, vol. 10, no. 8, pp. 1271-1286, 2011.
71. A.Vazquez-Martin, E. Lpez-Bonetc, S. Cuf-et al., Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesionsDrug ResistanceUpdates, vol. 14, no. 4-5, pp. 212-223, 2011.
72. S. Rice, L. Pellat, A. Ahmetaga, G. Bano, H. Mason, and S. Whitehead, Dual effect of metformin on growth inhibition and oestradiol production in breast cancer cells International Journal ofMolecularMedicine, vol. 35,no. 4, pp. 1088-1094, 2015.
73. C. Fan, Y. Wang, Z. Liu et al., Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer International Journal of Molecular Medicine, vol. 36, no. 1, pp. 204-214, 2015.
74. P. J. Goodwin, W. R. Parulekar, K. A. Gelmon et al., Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32 Journal of the National Cancer Institute, vol. 107, no. 3, Article ID djv006, 2015.
75. A.DeCensi, M. Puntoni, S. Gandini et al., Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial Breast Cancer Research and Treatment, vol. 148, no. 1, pp. 81-90, 2014.
76. J. Kim, W. Lim, E.-K. Kim et al., Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR) BMC Cancer, vol. 14, article 170, 2014.
77. M. Cazzaniga, A. DeCensi, G. Pruneri et al., The effect of metformin on apoptosis in a breast cancer presurgical trial British Journal of Cancer, vol. 109, no. 11, pp. 2792-2797, 2013.
78. S. Niraula, R. J. O. Dowling, M. Ennis et al., Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study Breast Cancer Research and Treatment, vol. 135, no. 3, pp. 821-830, 2012.
79. A. F. Santidrian, A.Matsuno-Yagi,M. Ritland et al., Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progressionThe Journal of Clinical Investigation, vol. 123, no. 3, pp. 1068-1081, 2013.
80. A. F. Salem, D.Whitaker-Menezes, A. Howell, F. Sotgia, and M. P. Lisanti, Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance Cell Cycle, vol. 11, no. 22, pp. 4174-4180, 2012.
81. W. W. Wheaton, S. E. Weinberg, R. B. Hamanaka et al., Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis eLife, vol. 3, Article IDe02242, 2014.
82. A. Emami Riedmaier, P. Fisel, A. T. Nies, E. Schaeffeler, and M. Schwab, Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects Trends in Pharmacological Sciences, vol. 34, no. 2, pp. 126-135, 2013.
83. L. M. Berstein, A. G. Iyevleva, D. Vasilyev, T. E. Poroshina, and E.N. Imyanitov, Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer Cell Cycle, vol. 12, no. 23, pp. 3681-3688, 2013.
84. Y. Shu, S. A. Sheardown, C. Brown et al., Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action The Journal of Clinical Investigation, vol. 117, no. 5, pp. 1422-1431, 2007.
85. X. Lin, C. A. David, J. B. Donnelly et al., A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 1, pp. 174-179, 2008.